Trials / Completed
CompletedNCT02207218
To Investigate Safety and Efficacy of NovoEight® (rFVIII) During Long-term Treatment of Haemophilia A in Japan
A Multicentre, Non-interventional Post Marketing Study of Safety and Efficacy of NovoEight® (rFVIII) During Long-Term Treatment of Haemophilia A in Japan
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 40 (actual)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This study is conducted in Asia. The aim of this study is to evaluate the safety and efficacy of NovoEight® (recombinant factor VIII) in patients with haemophilia A in Japan in the setting of routine clinical practice.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | turoctocog alfa | No treatment given. Patients will be treated with commercially available NovoEight®. Patients will be treated according to local clinical practice at the direction of the physician. |
Timeline
- Start date
- 2014-08-04
- Primary completion
- 2020-11-10
- Completion
- 2020-11-10
- First posted
- 2014-08-04
- Last updated
- 2021-11-15
Locations
2 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT02207218. Inclusion in this directory is not an endorsement.